IUPAC/Chemical Name
Butanoic acid, 2,2-diethyl-4-((3-(2-(4-(1-methylethyl)-2-thiazolyl)ethenyl)phenyl)amino)-4-oxo-, (E)-
InChi Key
PGLNVMJTDKEOBE-ZHACJKMWSA-N
InChi Code
InChI=1S/C22H28N2O3S/c1-5-22(6-2,21(26)27)13-19(25)23-17-9-7-8-16(12-17)10-11-20-24-18(14-28-20)15(3)4/h7-12,14-15H,5-6,13H2,1-4H3,(H,23,25)(H,26,27)/b11-10+
SMILES Code
O=C(O)C(CC)(CC)CC(NC1=CC=CC(/C=C/C2=NC(C(C)C)=CS2)=C1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
400.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Nagai H, Kitagaki K, Miura T, Shimazawa T, Koda A. Effect of a newly synthesized leukotriene antagonist, (E)-2,2-diethyl-3'-2-2-(4-isopropyl) thiazolyl ethenyl succinanilic acid (MCI-826), on immunological liver injury and nephritis in mice. Prostaglandins Leukot Essent Fatty Acids. 1992 Sep;47(1):51-7. PubMed PMID: 1438466.
2: Watanabe-Kohno S, Yamamura H, Nabe T, Horiba M, Ohata K. MCI-826 is a potent and selective antagonist of peptide leukotrienes (p-LTs) and has characteristics distinctive from those of FPL 55712. Jpn J Pharmacol. 1992 Sep;60(1):1-8. PubMed PMID: 1460800.
3: Miura T, Inagaki N, Goto S, Yoshida K, Nagai H, Koda A. Leukotriene receptors in the skin of rats differ from those of mouse skin or rat stomach strip. Eur J Pharmacol. 1992 Oct 20;221(2-3):333-42. PubMed PMID: 1330627.
4: Yamada N, Yamada K, Takahashi K, Nakao E, Kadowaki S, Umezu K. Pharmacological profile of the novel, potent and selective peptide leukotriene antagonist (E)-2,2-diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid. Arzneimittelforschung. 1994 Jun;44(6):749-53. PubMed PMID: 8053974.
5: Watanabe-Kohno S, Yasui K, Nabe T, Yamamura H, Horiba M, Ohata K. Significant role of peptide leukotrienes (p-LTs) in the antigen-induced contractions of human and guinea pig lung parenchymas and bronchi or tracheas in vitro. Jpn J Pharmacol. 1992 Nov;60(3):209-16. PubMed PMID: 1283422.
6: Nabe T, Yamashita K, Miura M, Kawai T, Kohno S. Cysteinyl leukotriene-dependent interleukin-5 production leading to eosinophilia during late asthmatic response in guinea-pigs. Clin Exp Allergy. 2002 Apr;32(4):633-40. PubMed PMID: 11972613.
7: Yamada N, Kadowaki S, Umezu K. Development of an animal model of late asthmatic response in guinea pigs and effects of anti-asthmatic drugs. Prostaglandins. 1992 Jun;43(6):507-21. PubMed PMID: 1410517.
8: Kohno S, Tsuzuike N, Yamamura H, Nabe T, Horiba M, Ohata K. Important role of peptide leukotrienes (p-LTs) in the resting tonus of isolated human bronchi. Jpn J Pharmacol. 1993 Aug;62(4):351-5. PubMed PMID: 8230862.
9: Tanpo T, Nabe T, Yasui K, Kamiki T, Kohno S. Participation of neuropeptides in antigen-induced contraction of guinea pig bronchi via NK(2) but not NK(1) receptor stimulation. Pharmacology. 2000 May;60(4):169-74. PubMed PMID: 10828740.
